EMJ Allergy & Immunology 10 [Supplement 3] . 2025

In this issue

Angioedema (AE) syndromes are associated with recurrent, unpredictable attacks of subcutaneous and submucosal tissue swelling, which can become life-threatening. Recent classification efforts define a group of rare forms of AE mediated by overproduction of the vasodilator bradykinin. To discuss the role of bradykinin in AE, the EMJ interviewed AE specialist Danny M. Cohn, University of Amsterdam, the Netherlands. Cohn described the manifestations (attacks), pathogenesis, and diagnosis of bradykinin-mediated forms of AE, and considered the unmet treatment needs in these patients. The potential for new therapies targeting the bradykinin B2 receptor was discussed, alongside recent data for bradykinin B2 receptor antagonism.